Skip to main content
ACIU logo

AC Immune SA

ACIUNASDAQHealthcareBiotechnology

$2.31Today:- (-)1Y −11.03%

As of Oct 26, 2026 close

Market cap
$254.71M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$2.10$4.00
Volume (live)
-
Avg. volume (3M)
179.24K

AC Immune SA (ACIU) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), AC Immune SA used CHF 69.26M of cash in operating activities and spent CHF 900.00K on capital expenditures. That left free cash flow of −CHF 70.16M.

AC Immune SA Cash Flow Statement Analysis

Values in millions CHF

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for AC Immune SA (ACIU) - Annual data in millions CHF
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-67.28-50.92-54.23-70.75-73.00-61.9245.44-50.95-26.41
Depreciation & Amortization2.502.162.222.362.411.971.690.960.58
Deferred Income Tax0.000.000.000.000.130.000.000.130.18
Stock Based Compensation4.405.474.373.334.134.092.832.521.58
Change in Working Capital-6.78107.51-15.16-8.436.84-4.575.651.81-1.99
Change in Accounts Receivable0.8813.55-14.870.600.50-0.532.500.70-0.40
Change in Accounts Payable-0.590.980.770.00-0.080.000.000.00-2.85
Change in Other Working Capital0.923.57-1.33-9.040.32-4.043.151.810.86
Other Operating Activities0.920.181.99-0.07-5.590.92-0.401.453.97
Net Cash from Operating Activities-69.2665.84-60.41-73.57-65.69-59.5255.22-44.08-22.09
Investing Activities
Capital Expenditures-0.90-0.58-0.80-1.24-2.64-1.71-1.89-1.86-1.80
Acquisitions0.010.000.000.000.000.000.000.000.00
Purchases of Investments0.00-104.6666.450.00-51.000.00-65.00-30.000.00
Sales/Maturities of Investments61.690.000.000.000.000.000.000.000.00
Other Investing Activities-0.16-0.0566.4525.00-0.0330.040.00-0.18-0.04
Net Cash from Investing Activities63.54-105.2965.6523.76-53.6628.33-66.89-32.04-1.84
Financing Activities
Debt Repayment-1.03-0.68-0.55-0.57-0.51-0.9550.060.200.20
Common Stock Issued0.010.1143.800.0117.800.100.00111.530.00
Common Stock Repurchased0.000.000.00-0.010.00-0.100.000.000.00
Other Financing Activities0.05-0.55-0.55-0.78-0.010.14-0.44-2.350.07
Net Cash from Financing Activities-1.02-1.1243.25-1.3540.75-0.8049.62109.380.27
Summary
Effect of Forex Changes on Cash-2.74-1.65-1.580.52-0.07-0.70-0.83-1.18-4.17
Net Change in Cash-6.74-42.2246.91-50.63-78.68-32.6937.1332.09-27.83
Cash at Beginning of Period36.2878.4931.5982.22160.89193.59156.46124.38152.21
Cash at End of Period26.8036.2878.4931.5982.22160.89193.59156.46124.38
Free Cash Flow-70.1665.27-61.21-74.81-68.32-61.2253.34-45.94-23.90
Supplemental Disclosures
Interest Paid-0.130.180.480.470.35---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About AC Immune SA Cash Flow

What is AC Immune SA's free cash flow?

AC Immune SA had negative free cash flow of CHF 70.16M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −CHF 69.26M minus CHF 900.00K of capital expenditures.

How much does AC Immune SA spend on capital expenditures?

AC Immune SA spent CHF 900.00K on capital expenditures in fiscal 2025, compared with CHF 576.00K a year earlier.

Does AC Immune SA pay dividends or buy back shares?

AC Immune SA's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition